Tratamiento hormonal en los pacientes con cáncer de mama de tipo luminal - page 38

Mutación ESR1

Mutation prevalence

Failed 1st line

33%

1st line

11%

(exposure only adjuvant setting)

ESR1 Mutations in Cell-Free DNA (ddPCR)

BOLERO-2 Clinical Trial

(2) Chandarlapaty S ET AL. JAMA Oncol. 2016;2(10):1310-1315

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,28,29,30,31,32,33,34,35,36,37 39,40,41,42